Fat Loss Research Peptides

25 research peptides demonstrate fat loss properties. This collection covers their mechanisms, evidence base, and research applications.

Semaglutide is an FDA-approved peptide utilized for the management of type 2 diabetes (marketed as Ozempic) and chronic weight management (under the brand name Wegovy). It is also indicated for the treatment of non-cirrhotic steatohepatitis (MASH) with no generic alternatives currently available. The FDA has issued warnings regarding counterfeit products, emphasizing the importance of sourcing from reputable suppliers.

Mechanistically, semaglutide acts as a GLP-1 receptor agonist, mimicking the endogenous GLP-1 hormone. It binds to receptors in pancreatic beta cells, the hypothalamus, and the gastrointestinal tract, leading to enhanced insulin secretion, suppressed glucagon release, and delayed gastric emptying. This multi-faceted approach promotes a sustained feeling of fullness, thereby reducing overall food intake. Notably, the injectable form has an approximate bioavailability of 89%, while the oral formulation (Rybelsus) requires administration on an empty stomach to achieve its intended effects.

Tirzepatide is an FDA-approved peptide that functions as a dual agonist of the GLP-1 and GIP receptors, offering a novel approach to metabolic management. This 39-amino-acid peptide incorporates a C20 fatty di-acid moiety, facilitating enhanced albumin binding and enabling once-weekly dosing.

The dual action of tirzepatide significantly enhances glucose-dependent insulin secretion and suppresses glucagon levels, which are critical for maintaining glucose homeostasis. Additionally, it slows gastric emptying and increases satiety signaling, contributing to weight loss. Research suggests that the GIP component may synergistically enhance metabolic outcomes beyond GLP-1 alone, leading to greater weight reduction in clinical settings. Furthermore, tirzepatide has been shown to elevate serum adiponectin levels, an adipokine involved in lipid and glucose metabolism, suggesting potential cardioprotective benefits.

Ipamorelin is recognized as a selective growth hormone secretagogue (GHS) and is notable for its specificity in stimulating growth hormone (GH) release without significantly impacting cortisol or prolactin levels. This synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) operates through a unique mechanism that distinguishes it from other GHSs.

By selectively binding to the Growth Hormone Secretagogue Receptor (GHS-R1a) on pituitary somatotroph cells, ipamorelin initiates a cascade of intracellular events that increase cAMP levels and activate protein kinase A, leading to the pulsatile release of GH. Its structural design allows for targeted action, minimizing the common side effects associated with other GHSs like GHRP-6 or GHRP-2. Preliminary studies indicate that ipamorelin maintains its efficacy over extended periods, with a half-life of approximately 2 hours, necessitating multiple daily doses, but it does not appear to desensitize its receptors.

CJC-1295, a synthetic analogue of growth hormone-releasing hormone (GHRH), was originally developed for the treatment of HIV-associated lipodystrophy. This peptide exists in two forms: one with a Drug Affinity Complex (DAC) that extends its half-life to approximately 5.8-8.1 days, and another without DAC (Mod GRF 1-29) that provides a more physiological pulsatile release with a half-life of around 30 minutes.

Clinical trials have demonstrated that CJC-1295 can induce significant increases in GH and IGF-1 levels in healthy adults, with a dose-dependent response observed. The mechanism involves binding to GHRH receptors on pituitary somatotroph cells, stimulating GH gene transcription and release. While the DAC version provides prolonged GH elevation, concerns regarding potential receptor desensitization and insulin resistance have been raised. In contrast, the Mod GRF 1-29 variant mimics natural GH pulsatility, reducing these risks and preserving somatostatin's negative feedback.

AOD-9604 is a modified fragment of human growth hormone, specifically designed to retain its lipolytic properties while minimizing growth-promoting effects. Developed at Monash University, Australia, this peptide has undergone Phase I–II clinical trials and was granted Generally Recognized as Safe (GRAS) status by the FDA for food use in 2014, although its clinical development for obesity was ultimately halted.

The mechanism of AOD-9604 involves a dual-action approach: it promotes lipolysis by stimulating hormone-sensitive lipase through cAMP signaling while concurrently inhibiting lipogenesis. Research indicates that AOD-9604 can effectively stimulate fat breakdown even in models lacking beta-3 adrenergic receptors, suggesting an alternative pathway for its action. Importantly, AOD-9604 does not elevate IGF-1 levels, which alleviates concerns related to cancer risk and organ enlargement commonly associated with full-length HGH. Additionally, preliminary studies suggest it may enhance glucose tolerance by reducing visceral fat.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide derived from mitochondrial DNA, identified in 2015 by Lee et al. at the University of Southern California. Its role as a metabolic regulator is primarily attributed to its activation of AMP-activated protein kinase (AMPK). In preclinical models, particularly in mice, MOTS-c has shown promise in preventing diet-induced obesity and insulin resistance, significantly enhancing exercise capacity—older mice demonstrated a twofold increase in treadmill endurance. Additionally, it has been associated with mitigating age-related metabolic decline. Although a modified analog, CB4211, has entered Phase 1 human trials with favorable tolerability, no clinical trials have been conducted on the native MOTS-c peptide in humans. This absence of human data limits the translation of animal findings into clinical practice.

Sermorelin is a synthetic peptide composed of 29 amino acids, mirroring the initial segment of the natural growth hormone-releasing hormone (GHRH). Its design aims to stimulate the body's endogenous growth hormone (GH) production while preserving the natural feedback mechanisms, which enhances its safety profile compared to exogenous GH administration. The 1997 trial published in the Journal of Clinical Endocrinology and Metabolism (JCEM) provides substantial evidence for its efficacy in adults, indicating improvements in insulin-like growth factor 1 (IGF-1), body composition, and overall well-being over a five-month period. Sermorelin operates by binding to GHRH receptors in the anterior pituitary, promoting GH release, which in turn facilitates processes such as lipolysis and tissue repair. Its short half-life of approximately 11-12 minutes does not preclude the regenerative effects initiated by GH release, which may persist for extended periods. While promising, further studies are necessary to fully elucidate its long-term effects and optimal applications.

Tesamorelin is an FDA-approved synthetic peptide that functions as a growth hormone secretagogue, specifically designed to stimulate the release of endogenous growth hormone and subsequently increase IGF-1 levels. Its efficacy has been demonstrated in Phase 3 clinical trials, where it was shown to significantly reduce visceral fat over a treatment period of 26 weeks while maintaining a well-tolerated safety profile. The mechanism of action involves binding to growth hormone-releasing factor (GRF) receptors in the anterior pituitary, thereby enhancing the synthesis and release of GH. This process leads to increased lipolysis and a reduction in visceral adipose tissue, which is particularly relevant given the health risks associated with excess visceral fat. Additionally, tesamorelin modulates cytochrome P450 enzyme activity, potentially influencing the metabolism of concomitant medications. While the data support its clinical utility, ongoing research is needed to explore its long-term effects and broader applications in metabolic health.

GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide recognized for its role as a potent growth hormone secretagogue. By binding to the ghrelin receptor (GHS-R1a), it stimulates the pulsatile release of growth hormone from the pituitary gland while simultaneously maintaining physiological feedback mechanisms. Notably, GHRP-6 is one of the earliest peptides developed in this class, and it is characterized by its ability to stimulate appetite, a common effect associated with ghrelin receptor activation. Preclinical studies have highlighted its cytoprotective properties, including cardioprotective, neuroprotective, and anti-fibrotic effects, which may extend its utility beyond mere endocrine functions. GHRP-6's half-life is approximately 2.5 hours, and its interaction with the CD36 receptor on immune and muscle cells activates protective signaling pathways against oxidative stress and inflammation. Despite its potential, the transient increase in cortisol and ACTH levels observed with GHRP-6 may necessitate further investigation into its long-term effects and safety profile.

GHRP-2 (pralmorelin) is a synthetic hexapeptide that serves as a potent growth hormone secretagogue by activating the ghrelin receptor (GHS-R). Compared to GHRP-6, GHRP-2 is noted for its higher potency and lower stimulation of appetite. Approved in Japan as a diagnostic agent for growth hormone deficiency, GHRP-2 has been clinically utilized in children with GH deficiency for durations of 8 to 24 months, demonstrating maintained efficacy in growth velocity. Clinical studies have reported a safety profile akin to placebo at therapeutic doses, reinforcing its utility in clinical settings. The mechanism of action involves robust stimulation of GH release, with a typical dose of 100 mcg administered subcutaneously producing significant GH elevation in healthy adults. GHRP-2 maintains physiological feedback controls, contrasting with continuous GH administration, thus avoiding rapid desensitization (tachyphylaxis). While it also moderately stimulates cortisol and prolactin, the clinical significance of these effects remains to be fully characterized.

Retatrutide is an innovative investigational peptide that acts as a triple agonist, targeting the GIP, GLP-1, and glucagon receptors. Developed by Eli Lilly, it is currently undergoing multiple Phase 3 clinical trials, including the TRIUMPH-4 trial, which anticipates reporting significant weight loss outcomes alongside improvements in osteoarthritis-related pain by December 2025. The expected FDA approval timeframe is projected for 2027-2028. The mechanism of action for retatrutide involves a synergistic effect from the activation of three distinct pathways: GLP-1 reduces appetite and slows gastric emptying, GIP enhances insulin sensitivity and glucose control, while glucagon promotes increased energy expenditure and fat oxidation. This comprehensive approach not only facilitates reduced caloric intake but also stabilizes glucose levels and boosts metabolic rate, distinguishing retatrutide from dual agonists like tirzepatide by incorporating a glucagon-driven thermogenic effect. As research progresses, the full clinical implications and potential applications of retatrutide in metabolic health will become clearer.

Liraglutide, developed by Novo Nordisk, has received FDA approval as Victoza for the treatment of type 2 diabetes and as Saxenda for chronic weight management, marking it as the first GLP-1 agonist approved for obesity. Research indicates that liraglutide exerts its effects by binding to GLP-1 receptors on pancreatic β-cells, which leads to increased intracellular cAMP and promotes glucose-dependent insulin secretion. Additionally, liraglutide suppresses glucagon release, slows gastric emptying, and influences hypothalamic appetite centers, contributing to reduced food intake and enhanced satiety. The inclusion of a fatty acid side chain (C16 palmitic acid) facilitates non-covalent binding to albumin, significantly extending its half-life to approximately 13 hours. This pharmacokinetic profile allows for once-daily dosing, making it a practical option for long-term weight management.

Cagrilintide is a long-acting synthetic analog of human amylin, which is co-secreted with insulin by pancreatic beta cells. Developed by Novo Nordisk, it is currently undergoing Phase III trials and has an NDA filed, both as a standalone treatment and in combination with semaglutide (CagriSema). This combination aims to leverage complementary appetite pathways, with amylin targeting hindbrain satiety circuits and GLP-1 acting on hypothalamic and gut pathways. Research suggests that cagrilintide activates amylin receptors in the area postrema and other hindbrain regions, promoting meal-related satiety while also slowing gastric emptying and suppressing inappropriate glucagon release. Structural modifications, including a fatty acid side chain, extend its half-life to about one week, supporting once-weekly dosing. The ongoing studies will further clarify its efficacy and safety profile in diverse patient populations.

Survodutide is an investigational dual agonist of glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma. Currently in Phase III trials with an NDA filed, it presents a novel therapeutic approach by combining the appetite-suppressing effects of GLP-1 with glucagon's role in enhancing hepatic fat oxidation and energy expenditure. Preliminary findings indicate that survodutide has shown significant promise for metabolic dysfunction-associated steatohepatitis (MASH), achieving resolution in 83% of patients at the highest dose during Phase 2 trials. The dual mechanism of action involves simultaneous activation of glucagon receptors, which promotes hepatic lipid mobilization, and GLP-1 receptors, which mitigate glucagon's hyperglycemic effects through improved insulin secretion. This multifaceted approach could make survodutide particularly effective in addressing both obesity and associated liver conditions, although further research is needed to establish long-term outcomes and safety.

5-Amino-1MQ is a small molecule that selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme implicated in the metabolic dysregulation observed in obesity. While not a peptide, its mechanism of action is of interest in the context of metabolic research. NNMT is overexpressed in the adipose tissue of obese individuals and is known to divert nicotinamide, a precursor of NAD+, away from its salvage pathway. By inhibiting NNMT, 5-Amino-1MQ is theorized to increase intracellular levels of NAD+ and S-adenosylmethionine (SAM), potentially enhancing energy expenditure in adipocytes and reducing their size. Preclinical studies, such as those by Neelakantan et al. (2018), have demonstrated that NNMT inhibition can lead to reduced body weight and adipocyte size in diet-induced obese mice, without altering food intake. These findings, while promising, are currently limited to animal models and require further investigation to ascertain their applicability to human subjects.